Sanofi Finalizes Sale of Doliprane to American Fund CD&R
Sanofi is in the final stages of negotiations with the American investment fund Clayton, Dubilier & Rice (CD&R) for the sale of its subsidiary Opella, which includes the popular over-the-counter drug Doliprane. Despite receiving a competing offer from French fund PAI, Sanofi's president in France, Audrey Duval, confirmed that discussions with CD&R are progressing. This decision is part of Sanofi's broader strategy to refocus on innovation and growth within the pharmaceutical sector.
Employee Concerns and Strikes at Sanofi
The announcement of the sale has sparked unrest among employees at Sanofi's manufacturing sites in Compiègne and Lisieux, where workers have voted to renew strikes in response to fears about job security and the future of the facilities. Duval has assured employees that both sites are critical for Opella's growth and that operations will remain stable post-sale. She emphasized that the sites are profitable and expanding, aiming to alleviate concerns about potential layoffs and operational changes.
Political Implications and Government Reactions
The proposed sale has drawn significant political attention, with various stakeholders expressing concerns about the implications for French sovereignty and the pharmaceutical industry. The French government has intervened, seeking assurances regarding job security and operational continuity. Duval reassured that Sanofi will retain a 50% stake in Opella, allowing them a veto power on strategic decisions, thus ensuring that key operations will remain in France.
